UBS AM’s Apogee Therapeutics APGE Stock Holding History
Bought
Maintained
Sold
Other funds holding APGE
UBS AM's APGE Position: Q3 2026 in Review
UBS AM sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 66,433 shares — an estimated $8.82M sold.
UBS AM first reported a position in APGE in Q2 2024 and held it in 9 quarters. The position peaked at $8.82M in Q2 2026. 3 funds tracked by Wall St. Rank hold APGE as of Q3 2026.
- UBS AM reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
- UBS AM sold 66,433 Apogee Therapeutics shares in Q3 2026, an estimated $8.82M.
- UBS AM first reported a position in Apogee Therapeutics in Q2 2024 and held it in 9 quarters.
- UBS AM's Apogee Therapeutics position peaked at $8.82M in Q2 2026.
- 3 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.